Insights
Our Views Of The Future
Longevity: A Look Ahead
Longevity is undergoing a structural transition from "anti-aging" wellness to translational geroscience (turning prior discoveries into applicable therapies and products (or interventions)), with the global market projected to grow from $28.9 billion in 2025 to over $52.8 billion by 2035 including regenerative medicine. Over the next five to ten years, we expect a shift toward "longevity infrastructure," where the convergence of AI-driven drug discovery and epigenetic reprogramming moves the needle from managing symptoms to cellular rejuvenation with particular emphasis on and in gene therapy and the rapid adoption of digital biomarkers, providing the quantifiable "biological clocks" necessary for clinical validation. This evolution will be underpinned by a massive demographic tailwind—the 60+ population is set to reach 1.4 billion by 2030—transforming longevity from a niche vertical into the primary framework for 21st-century preventative medicine and a multi-trillion-dollar "longevity economy." March 2026
Cardiology: The Cardiometabolic Renaissance
Cardiology is undergoing its most significant transformation since the invention of the statin, driven by a convergence of RNA-targeted therapeutics and the GLP-1 revolution. Over the next decade, we will transition from daily pill burdens to biannual "vaccine-like" injections that silence the genes responsible for hypertension and hyperlipidemia, effectively "immunizing" high-risk populations against atherosclerosis. Simultaneously, we are seeing a structural heart "MedTech" explosion; minimally invasive transcatheter interventions are expanding from the aortic valve to the more complex mitral and tricuspid systems, capturing a massive, underserved geriatric demographic. From an investor perspective, we believe that outsized returns are achievable in the "Cardiometabolic Plus" space—companies leveraging the anti-inflammatory properties of obesity drugs to treat heart failure and chronic kidney disease, creating a multi-indication "platform" effect that maximizes terminal value while minimizing trial failure risk. March 2026
Oncology: From Mass Blockbusters to Precision Curatives
In the next five to ten years, oncology will shift from "managing" systemic disease to "eradicating" it through molecularly-defined precision. We are moving beyond first-generation immuno-oncology into an era dominated by Antibody-Drug Conjugates (ADCs) and multi-specific antibodies that act as "guided missiles," delivering cytotoxic payloads directly to malignant cells while sparing healthy tissue. The investment opportunity lies in the "de-risking" of solid tumor targets; expect a surge in allogeneic (off-the-shelf) cell therapies that bypass the logistical bottlenecks of current autologous CAR-T treatments, making curative-intent medicine an outpatient reality. By 2030, AI-integrated multi-omics will allow us to move "left of the curve," identifying and treating stage 1 and 2 cancers with the same intensity we currently reserve for terminal cases, fundamentally reclassifying metastatic cancer into a manageable, and often curable, chronic condition. February 2026
Gemini said Capitalizing High-Yield Health and Life Science Enterprises
Innovation
At Cerdwen, we believe in pushing the boundaries of what's possible. Our commitment to innovation drives us to invest in groundbreaking life science, health, longevity and biotech ventures that transform lives.
Integrity
Trust is foundational to our business. We conduct our business with the highest ethical standards, ensuring transparency and accountability in all our partnerships and investments.
Collaboration
We seek collaboration, fostering real relationships with entrepreneurs, scientists, and fellow investors. Together, we build a community dedicated to advancing healthcare solutions.
Impact
Excellence
The Future of Health Innovation
We aim to transform the future of well-being at every level with our strategic investments.